|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Hypertension moderated the effects of APOE ε4 on the rate of change for cognitive flexibility, such that the presence of the APOE ε4 allele and hypertension was associated with steeper cognitive decline over a 21-year period.
|
24956008 |
2014 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
APOE (HhaI) and APOB (XbaI and Ins/Del) polymorphisms were not associated with hypertension or variations in serum concentrations of lipids, while subjects with the APOB E- allele had higher low-density lipoprotein cholesterol (LDL-C) levels than E+ carriers (P<0.05).
|
15543563 |
2004 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E (apoE) gene polymorphism is one of the most well-studied genetic markers for vascular diseases, including hypertension.
|
15674008 |
2004 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E gene (ApoE) is one such candidate with its common ɛ2/ɛ3/ɛ4 polymorphism ranking high in hypertension association.
|
21228824 |
2011 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOE genotype significantly modified the associations between both midlife hypertension and cardiovascular disease and decline in language abilities and midlife diabetes and decline in verbal memory, attention, and visuospatial abilities.
|
23601373 |
2013 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
APOE ɛ4 remained significant (OR: 2.37; 95% CI: 1.37, 4.07), as did hypertension (OR: 0.55; 95% CI: 0.32, 0.93).
|
28578665 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population.
|
31559922 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure.
|
9531184 |
1998 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
A custom rat and baboon hypertension gene array to compare experimental models.
|
22228705 |
2012 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
A propensity score analysis was used to model the association of APOE with the burden of hypertension across race/ethnic groups.
|
30726504 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Altered FBS was found in 28.3% of the participants, hypertension in 57.6% and APOE4 in 32.0%.
|
30205523 |
2018 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
An overall comparison of the ApoE gene alleles ɛ4 with ɛ3 yielded a significant 81% increased risk for hypertension (95% confidence interval (95% CI): 1.41-2.32; P<0.0005).
|
22113353 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Analyses included APOE genotype, gender, ethnicity, body mass index, and other potential confounders such as a history of hypertension, smoking, aspirin use, previous stroke, or ischemic heart disease.
|
10449113 |
1999 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Black race (hazard ratio [HR], 1.36; 95% CI, 1.21-1.54), older age (HR, 8.06; 95% CI, 6.69-9.72 for participants aged 60-66 years), lower educational attainment (HR, 1.61; 95% CI, 1.28-2.03 for less than a high school education), and APOE ε4 genotype (HR, 1.98; 95% CI, 1.78-2.21) were associated with increased risk of dementia, as were midlife smoking (HR, 1.41; 95% CI, 1.23-1.61), diabetes (HR, 1.77; 95% CI, 1.53-2.04), prehypertension (HR, 1.31; 95% CI, 1.14-1.51), and hypertension (HR, 1.39; 95% CI, 1.22-1.59).
|
28783817 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Cardiovascular risk factors such as high serum cholesterol, presence of the Apolipoprotein epsilon4 (APOE epsilon4) allele and hypertension, play important roles in the development of Alzheimer's disease.
|
18378224 |
2008 |
|
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Carriers of the ESR1 p allele had significantly greater declines in logical memory compared to participants with the PP genotype, independent of demographic characteristics (e.g. age), chronic illness (e.g. hypertension), sleep aid usage, hormone levels, apolipoprotein E e4 status and prospective changes in mood, smoking and alcohol consumption.
|
23128795 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Consecutive outpatients with late-onset AD were assessed for APOE haplotypes and the following potential baseline predictors: gender, schooling, age at dementia onset, lifetime urban living and sanitary conditions, occupational complexity, cognitive and physical activities, cerebrovascular risk factors (obesity, lifetime alcohol use and smoking, length of arterial hypertension, diabetes mellitus, and a dyslipidemic profile), use of a pacemaker, creatinine clearance, body mass index, waist circumference, head traumas with unconsciousness, treated systemic bacterial infections, amount of surgical procedures under general anesthesia, and family history of AD.
|
30149448 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.
|
20720404 |
2010 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Exploiting Drug-Apolipoprotein E Gene Interactions in Hypertension to Preserve Cognitive Function: The 3-City Cohort Study.
|
30292766 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Exploratory analyses revealed that the strongest effect of APOE epsilon4 was in subjects age <65 (OR 3.08, CI 1.43 to 6.64), and was stronger in those with hypertension or cardiovascular disease than in those without.
|
15326239 |
2004 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
For ApoE genotypes, compared with ε3/ε3 genotype, genotypes (ε2/ε2 and ε2/ε3) showed a possible association with hypertension (OR = 0.88; 95% CI: 0.79-0.99; P = 0.033), and genotypes (ε3/ε4 and ε4/ε4) had a 2.08-fold risk of developing hypertension (OR = 2.08; 95% CI: 1.58-2.74; P < 0.001).
|
30180966 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Further, that APOE4 predisposes the CV to damage by, and exacerbates the effects of, additional risk factors (such as sex, hypertension, and diabetes).
|
26884068 |
2016 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, after restricting our analysis to Asian populations, the contrasts between the risk of hypertension among individuals possessing ApoE epsilon4 vs. epsilon3 and ApoE4/4 vs. ApoE3/3 were positively reinforced, with ORs of 1.97 (95% CI, 0.93 to 4.15; P=0.08) and 2.27 (95% CI, 1.03 to 4.98; P=0.04), respectively.
|
19816504 |
2009 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
GWASCAT |
Genetic heterogeneity of Alzheimer's disease in subjects with and without hypertension.
|
31055733 |
2019 |
|
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
BEFREE |
Importantly, our results indicated a significant association between ApoE promoter methylation and ACI (OR = 16.146; 95% CI, 1.154-225.832; P* < .05; P*: adjusted for age, gender, carotid atherosclerotic plaque, hypertension, HDL-C, homocysteine, and folate) (Table 4).
|
30658954 |
2019 |